
PFE
USDPfizer Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$24.330
High
$24.630
Low
$24.111
Volume
107.02M
Company Fundamentals
Market Cap
138.9B
Industry
Drug Manufacturers - General
Country
United States
Trading Stats
Avg Volume
57.95M
Exchange
NYQ
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Nov 10, 2025Pfizer (PFE) - A Balanced Playbook for a $139B Pharma Giant
Key Takeaway: Pfizer is a hold-and-wait story. The stock is stuck in a tight $24-$25 range, but the fundamentals remain solid. A break above $25.50 or below $23.50 will decide the next 10-15% move. Until then, the risk-reward is neutral.
1. Price Action - Stuck in a Box
- Current price: $24.42 (Nov 10 close)
- Resistance: $25.50 (needs a close above this level to trigger a fresh leg higher)
- Support: $23.50 (a close below this level would open the door to a retest of the $22-$23 zone)
Translation: Pfizer is trading in a tight $2 range. A decisive close above $25.50 or below $23.50 is needed to break the stalemate.
2. Fundamental Snapshot - Still a Cash Cow
- Revenue: $13.9B quarterly (down 3% YoY, but still strong)
- Free Cash Flow: $4.1B (ample to cover the $1.6B dividend and buybacks)
- Debt: $33.5B (manageable; interest coverage ratio 8.3x)
Translation: The balance sheet is rock-solid. The dividend is safe, and the company has plenty of firepower for bolt-on acquisitions or share buybacks.
3. Catalysts to Watch
- Pipeline: RSV vaccine (Abrysvo) is tracking for a $1B+ annual sales peak.
- M&A: Rumors of a mid-sized bolt-on deal in the $5-10B range.
- Buyback: $1.5B remaining on the current authorization.
Translation: These are the three near-term catalysts that could break the stock out of its range.
4. Analyst Sentiment - Wall Street Still Likes the Story
- 21 Buy ratings (vs. 3 Holds, 0 Sells)
- Average price target: $28.75 (17% upside to current price)
Translation: Analysts are bullish, but the stock is stuck in a range. The Street is waiting for a catalyst to unlock value.
5. How to Play It
- If you own it: Hold. The risk-reward is neutral until a clear break of the range.
- If you're looking to buy: Wait for a clear close above $25.50 or below $23.50 before making a move.
- Options play: The $25 calls expiring in 3 months are pricing in a 7% move. That's a cheap way to play a breakout.
Bottom Line
Pfizer is a hold-and-wait story. The stock is stuck in a range, but the company is still a cash machine. The next 10-15% move will be decided by a break above $25.50 or below $23.50. Until then, the risk-reward is neutral.
This is not financial advice. Consult a licensed professional before making any investment decisions.
Related News
Major deals involving U.S. drugmakers and biotechs over the past decade
Pfizer won a $10 billion bidding war for Metsera , beating Danish rival Novo Nordisk , securing access to the U.S. biotech's experimental obesity drug assets.
Norway's sovereign wealth fund to abstain from Novo Nordisk board vote
Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members at drugmaker Novo Nordisk's extraordinary shareholders' meeting this week, including the proposed new chairman.
Novo Nordisk shares rise after dropping Metsera bid
Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its bid for U.S. weight loss drug company Metsera, ending a bidding war with rival Pfizer .
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports
Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter.
Pfizer Q3 Revenue Trends Remain Uneven, Cost Cuts Drive Earnings
Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs.
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.
AI PredictionBeta
AI Recommendation
Updated at: Nov 10, 2025, 08:53 AM
58.8% Confidence
Risk & Trading
Entry Point
$24.31
Take Profit
$25.59
Stop Loss
$21.99
Key Factors
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.